# Rallybio Corporation (RLYB)

> Source: Nexqual · https://nexqual.com/RLYB · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Rallybio Corporation (RLYB), nexqual.com/RLYB" · informational, not investment advice.

**Price:** USD 16.4 (+0.52% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 16.32 · day 16.2–16.4 · 52w 3.67–17.57 · market cap $87.1M · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $646K, net income $45.6M (7051.2% margin) (SEC filings).
- Valuation: P/E 1.9x.
- 1 of 80 tracked superinvestors hold RLYB (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Total return with dividends: 1Y +241.7% vs S&P 500 +14.9%; 5Y -87.4% vs S&P 500 +80.3%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $636K | $858K | $646K |
| Operating income | -$45.6M | -$67.9M | -$78.9M | -$60.5M | -$33.1M | -$27.7M |
| Net income | -$47.0M | -$66.7M | -$74.6M | -$57.8M | -$9.0M | $45.6M |
| EPS (diluted) | -$14.72 | -$16.72 | -$14.72 | -$10.61 | -$1.59 | — |
| Free cash flow | -$45.9M | -$57.3M | -$60.3M | -$49.3M | — | — |
| Operating margin | — | — | — | -9511.9% | -3853.6% | -4291.5% |
| Net margin | — | — | — | -9084.1% | -1046.4% | 7051.2% |
| Revenue growth | — | — | — | — | +34.9% | — |
| Cash + short-term investments | $175M | $169M | $110M | $65.5M | $54.7M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 1.9x · P/S 134.9x · P/B 0.9x · Earnings yield 52.28%

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold RLYB. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.02% | $8.4M | Unchanged |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +241.7% | -87.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +243.1% | -33.8% |
| Volatility (annualized) | 76.5% | 96.7% |
| Max drawdown | -31.1% (Dec 2025→Feb 2026) | -98.7% (Nov 2021→Apr 2025) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/RLYB · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name RLYB in their own reports (relationship from RLYB's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | RECURSION PHARMACEUTICALS, INC. (RXRX) | 10-K 2026-02-25 | "In addition to capital raising issuances, in connection with the acquisitions of Cyclica Inc. (Cyclica) and Valence Discovery Inc. (Valence) in May 2023, we issued 12.4 million shares of our Class A c…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-1.44 | $-1.44 | +0.0% | $0 | 1 |
| Next quarter (ends 2026-12-31) | $-1.60 | $-1.60 | +0.0% | $0 | 1 |
| Current fiscal year (ends 2026-12-31) | $-5.52 | $-9.17 | -39.8% | $0 | 1 |
| Next fiscal year (ends 2027-12-31) | $-3.60 | $-3.60 | +0.0% | $0 | 1 |